# A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical Cancer

> **NCT07348861** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Zheng Min** · enrollment: 25 (estimated)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** Sacituzumab tirumotecan plus Iparomlimab

## Key facts

- **NCT ID:** NCT07348861
- **Lead sponsor:** Zheng Min
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2028-01-01
- **Final completion:** 2028-01-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-01-16

## Collaborators

- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Qilu Pharmaceutical Co., Ltd.

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07348861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07348861, "A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical Cancer". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT07348861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*